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Summary. Aim: Zinc (Zn) deficiency has been shown to be associated with age-related eye diseases, such as 
diabetic retinopathy. Blood sugar and blood pressure are prognostic factors in diabetic retinopathy. The aim 
of this study was to evaluate the effects of zinc supplementation on diabetes indices and blood pressure in 
patients with non-proliferative diabetic retinopathy. Patients and Methods: 45 patients with non-proliferative 
diabetic retinopathy (20 males and 25 females) aged from 40 to 70 years were participated in current double-
blind randomized placebo-controlled trial. The disease was diagnosed by an expert ophthalmologist accord-
ing to early photocoagulation and diabetic retinopathy criteria. The patients were assigned to intervention 
(23 patients) and placebo (n = 22) groups. The groups received zinc (as zinc gluconate; 30 mg) and placebo 
(maltodextrin; 30 mg) for 3 months, respectively. Fasting insulin, fasting glucose, insulin resistance index 
(HOMA-IR), hemoglobin A1c (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP) and 
serum zinc levels were measured before and after the intervention in the both groups. Results: Zinc supple-
mentation significantly increased serum zinc (P= 0.004) and decreased serum insulin levels (P= 0.008), fasting 
blood sugar (FBS) (P= 0.011), HOMA-IR (P= 0.002) and SBP (P= 0.017) in the intervention group compared 
with placebo group. The intervention had no significant effects on DBP, HbA1c. Conclusion: Due to the posi-
tive effects of zinc supplementation on prognostic factors of diabetic retinopathy, it seems complementary 
therapy with zinc is needed in these patients.
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O r i g i n a l  a r t i c l e
Introduction 
Diabetic retinopathy is one of the microvascular 
complications of diabetes. Progression of non-prolif-
erative diabetic retinopathy causes rupture of newly 
formed blood vessels, vitreous hemorrhage, retinal de-
tachment and ultimately fibrosis (proliferative diabetic 
retinopathy) (1). The complication involves 80% of 
more than 10 year diabetics. Despite effective treat-
ments, diabetic retinopathy is still the leading cause of 
blindness (2). 
Many factors have been identified as prognostic 
factors for this complication which SBP, control blood 
sugar and nutrient deficiencies are more important 
prognostic factors of diabetic retinopathy which play 
a pivotal role in the progression of non-proliferative 
diabetic retinopathy and subsequently proliferative 
retinopathy (3-5). It has been suggested that blood 
sugar and blood pressure serve as prognostic factors in 
occurrence of diabetic retinopathy (6).
Zinc is one of the micro-nutrients that possess 
an important role in various metabolic reactions. Im-
pairment in zinc metabolism could be possible causes 
of blood pressure and blood sugar increment in dia-
betic patients. On the other hand zinc is accumulated 
with high concentrations in ocular tissue, particularly 
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in the retina and choroid. Recent studies have shown 
that zinc deficiency has role in pathogenesis of cata-
ract, age-related eye damage and even diabetic retin-
opathy (7). Jyothirmayi et al. in a cross sectional study 
showed that a serum levels of zinc and sugar  are 
lower and higher respectively in patients with diabetic 
retinopathy compared with patients without diabetic 
retinopathy (8). Further, it is known that  as diabetic 
retinopathy progresses serum zinc level reduce and 
FBS increase (5). There is a vicious cycle between zinc 
metabolism and diabetes, so that diabetes increases the 
excretion of zinc and zinc deficiency exacerbates diabe-
tes complications (9, 10). Considering the importance 
of control of diabetes indices in positive prognosis of 
diabetic retinopathy and also absence of any study that 
evaluated the effects of zinc supplementation in dia-
betic retinopathy, the aim of this study was to evaluate 
the effects of zinc supplementation on serum insulin, 
FBS, insulin resistance index, HbA1c and blood pres-
sure in patients with diabetic retinopathy.
Patients and Methods
Study design
This study is a double-blind RCT that was car-
ried out among patients with non-proliferative dia-
betic retinopathy referred to diabetes clinic of Imam 
Khomeini and Alavi hospitals, under the supervision 
of Ardabil University of Medical Sciences, in Arda-
bil, North West of Iran. The study design and protocol 
has been approved by the ethic committee of Tabriz 
University of medical sciences and written informed 
consent was obtained from patients prior participation 
in the study. This study was registered in the Iranian 
Registry of Clinical Trial (www.irct.ir) with registra-
tion number ID: IRCT2014040617150N1.
The study’s inclusion criteria were as follows: ages 
between 40 to 70 years and having diabetic non-prolif-
erative retinopathy according to the early photocoagu-
lation for diabetic retinopathy (ETDRS) and diabetic 
retinopathy study (DRS) criteria. Exclusion criteria 
were as follows: having cardio vascular disease, kidney 
or  liver disease, taking drugs interfering with the se-
rum level of, taking insulin, being pregnant and lac-
tating, alcoholism, AIDS, infectious diseases and tak-
ing zinc containing dietary supplements three months 
prior participation in the study. 
In this study, from total of 180 diabetic patients 
examined, 50 patients were diagnosed with non-
proliferative diabetic retinopathy and enrolled in the 
study. During the study period, 2 persons in the sup-
plement group and 3 person in control group were 
excluded due to changes in medications and hospi-
talization. Thus, the study was carried out with 23 
patients in the intervention group and 22 patients in 
the placebo group. The study subjects were assigned 
into intervention (23 patients) and placebo (n = 22) 
groups by block randomization to receive zinc (zinc 
gluconate; 30 mg) and placebo (maltodextrin; 30 mg) 
for 3 months, respectively. Two treatment groups were 
matched by age, gender. Zinc gluconate and placebo 
tablets were prepared by Jalinous pharmaceutical com-
pany (Tehran, Iran) and department of pharmaceutics 
at Tabriz university of Medical Sciences, respectively.
Dietary and anthropometric assessment 
At baseline, end of sixth week and end of the 
study, 24-hour dietary recall was completed. Further, 
before and after the intervention anthropometric pa-
rameters (height, weight, waist and hip circumference) 
were measured and BMI (body mass index) and WHR 
(waist to hip ratio) were calculated. SBP and DBP also 
were measured before and after the study. WHR is 
the ratio of the circumference of the waist to that of 
the hips. BMI was defined as the body weight (kg) di-
vided by the square of the body height (m).
Physical activity
Physical activity was evaluated in MET-minutes/
week using international physical activity question-
naire (IPAQ) at first, middle and end of the study.
Biochemical assays
Fasting blood samples were obtained from all 
of the participants at the beginning and end of the 
trial. The serum and plasma samples were separat-
ed by centrifugation at 2500 rpm for 10 minutes at 
room temperature. The serum samples were stored at 
-70°C immediately until their assays. Insulin, HbA1c, 
FBS and serum zinc were measured using turbidim-
etry, chemiluminescence, enzymatic colorimetric and 
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atomic absorption spectrophotometry methods, re-
spectively. Insulin resistance index was calculated us-
ing the HOMA-IR formula (fasting plasma glucose 
(mmol/l) multiplied by fasting serum insulin (mU/l) 
divided by 405).
Statistical assays
Statistical analysis was performed by SPSS soft-
ware (SPSS Inc., Chicago, IL, USA). Quantitative 
and qualitative data were presented as mean ± stand-
ard deviation and frequency (percent) respectively. For 
data analysis, independent sample t-test, Paired t-test, 
chi-square, linear regression and repeated measure test 
were used. For confounder adjustment, Analysis of co-
variance (ANCOVA) was used. 
Results
The flowchart of the study has been shown in Fig-
ure 1. Totally, 45 patients completed the study. General 
characteristics of the study participants are presented in 
Table 1. Age, gender, smoking status, diabetes duration 
and physical activity levels were not different between 
the groups. Further, no significant changes were ob-
served in dietary energy, protein, fat, carbohydrate and 
zinc during the study period (Table 2). The changes 
of HbA1c, DBP, BMI and WHR were not statisti-
cally significant after the zinc treatment as compared 
with placebo receiving group. Serum concentrations of 
insulin significantly reduced after treatment with zinc 
(P<0.05) but not in the placebo group. Levels of FBS in 
the zinc treated group reduced from 182.04 ± 64.88 to 
162.95 ±48.44. Also, SBP decreased from 129.17±14.73 
to 125.43±13.57. However, serum zinc increased from 
69.91±6.16 to 75.78±7.24. There was a reduction in 
HOMA-IR in this group (P= 0.002). None of these 
changes occurred in placebo-treated group. In com-
parison of mean differences between before and after 
intervention values of mentioned variables, mean re-
duction of insulin, FBS, zinc, HOMA-IR and not SBP 
in the zinc treated group were significantly meaningful 
Figure 1. Flow diagram of subject recruitment.
Table 1. Participants demographic characteristics 
Variables  Groups P-value
  Intervention Placebo 
Sex [n (%)] male 10(43.5) 10(45.5) 0.894°
 female 13(56.5) 12(54.5) 
Smoking [n (%)] yes 4(17.4) 4(18.2) 0.624°
 no 19(82.6) 18(81.8) 
Physical activity [n (%)] low 17(73.9) 19(86.4) 0.459°
 moderate  6(26.1) 3(13.6) 
Age (mean± SD)  57.43±5.75 57.95±5.89 0.766#
Diabetes duration (mean± SD)  8.78±4.67 9.86±4.95 0.456#
BMI (mean± SD)  27.71±4.60 28.79±4.77 0.444#
WHR (mean± SD)  0.96±0.06 0.99±0.04 0.103#
°P-value based on chi-square test; #P-value based on independent sample T test
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in comparison of placebo-treated group (Table 3). Al-
though the study results revealed zinc supplementation 
have positive effects on the biochemical parameters but 
evaluation of the association of before intervention se-
rum zinc with biochemical parameters showed no sig-
nificant association (Table 4).
Discussion
Blood sugar is one of the prognostic factors in di-
abetic retinopathy. Control of prognostic factors plays 
a significant role in progression of non-proliferative 
diabetic retinopathy to proliferative diabetic retinopa-
thy (3, 5). In this study, zinc supplementation resulted 
in a significant reduction in insulin, FBS levels and 
HOMA-IR in patients with non-proliferative diabetic 
retinopathy. There is any study to evaluate supplemen-
tation with zinc in patients with diabetic retinopathy. 
It has been known that progression of diabetic retin-
opathy leads to depletion of zinc deposits in the body 
and exacerbate hyper-glycaemia (5, 11). Ishihara et al, 
in a cross-sectional study, to assessed blood sugar lev-
els in patients with diabetic retinopathy revealed that 
blood glucose levels in these patients was higher than 
those without retinopathy (12). In a similar study gan-
iger et al showed that not only blood sugar levels in pa-
tients with diabetic retinopathy was higher than those 
without retinopathy, but the serum zinc of the patients 
was less than control group. Also the authors reported 
an inverse association of serum zinc and HbA1c (13).
Many studies reported imbalance between oxi-
dant and antioxidant status in people with diabetes. 
The improvement in antioxidant status may have role 
in enhancing insulin action. Accumulation of free rad-
icals may play a pivotal role in complications of diabe-
tes potentially. Among the factors causing free radicals 
formation can be noted to hyperglycemia, hyperinsu-
linemia and or insulin resistance (14, 15). Roussel et al. 
in an interventional study showed that supplementa-
tion with zinc improves antioxidant status in patients 
with type 2 diabetes (16). Zinc plays a key role in the 
stability of the insulin structure. This micronutrient 
stores insulin by linking insulin containing vacuoles to 
cell membranes. On the other hand the element  is a 
powerful antioxidant for oxidizing agents removal (17, 
18). Given the role of oxidative stress in initiation and 
progression of diabetes and insulin resistance, zinc de-
ficiency can have a central role in diabetes complica-
tions (19, 20). 
Table 2. Assessment of dietary factors (mean± SD) during the study   
Variables	 Time	points		 	 P-value•
  before middle After 
Energy (Kcal)  Intervention 1495.47±581.05 1526.35±427.01 1557.14±631.62 0.256
 Placebo 1447.23±439.31 1385.10±480.19 1598.63±401.36 0.156
 P-value# 0.756 0.302 0.795 
Zinc (mgr) Intervention 5.52±2.86 5.73±2.81 5.81±4.01 0.286
 Placebo 4.58±3.00 5.82±3.23 5.24±2.88 0.723
 P-value# 0.288 0.916 0.591 
CHO (gr) Intervention 242.49±124.98 255.34±90.98 252.62±138.36 0.614
 Placebo 244.45±91.55 245.38±77.28 276.13±98.18 0.748
 P-value# 0.952 0.695 0.517 
FAT (gr) Intervention 31.81±19.20 31.92±14.92 34.32±27.07 0.298
 Placebo 28.52±20.24 34.31±17.19 31.35 0.198
 P-value 0.578 0.621 0.656 
Protein (gr) Intervention 62.59±27.72 60.62±19.53 62.40±26.62 0.386
 Placebo 55.43±20.28 62.02±24.07 60.35±14.19 0.137
 P-value# 0.330 0.831 0.750 
•P-value based on repeated measure test;# P-value based on independent sample t test  
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Blood pressure, like blood sugar, is one of the 
prognostic factors in patients with diabetic retinopathy. 
Control of blood pressure in people with diabetes can 
prevent the exacerbation of microvascular complications 
(21). In this study, zinc supplementation significantly 
reduced SBP. There is no report to evaluate the effects 
of supplementation with zinc in patients with diabetic 
retinopathy. Schrier et al. in a five years follow up pro-
spective study demonstrated control of blood pressure 
significantly reduce diabetic retinopathy progression 
(22). In another cohort study Muir et al. reported that 
Table 3. Diabetic indices (Mean ± SD) following zinc treatment
Variables Groups P-value•
 Intervention Placebo 
  Mean ± SD Percent change Mean ± SD Percent change
Insulin (mIU/ml) Before 8.47±4.84 -16.84 10.62±3.25 -5.14 0.008
 After 6.42±3.64  10.07±3.85
 P-value# 0.007  0.324
FBS (mg/dl) Before 182.04±64.88 -7.65 194.31±45.34 4.64 0.011
 After 162.95±48.44  200.27±55.9
 P-value# 0.012  0.549  
HOMA-IR Before 3.80±2.44 21.04 5.07±1.81 -0.32 0.002
 After 2.50±.38  5.14±2.89 
 P-value# 0.002  0.879  
HbA1c (%) Before 8.54±1.78 -2.48 8.90±1.54 3.36 0.079
 After 8.22±1.57  9.02±1.27  
 P-value# 0.250  0.671  
SBP (mm Hg) Before 129.17±14.73 -2.61 126.72±12.25 2.40 0.017
 After 125.43±13.57  129.40±11.44  
 P-value# 0.048  0.167  
DBP (mm Hg) Before 74.73±9.97 -2.12 76.50±8.70 2.85 0.195
 After 72.65±9.85  78±7.95  
 P-value# 0.236  0.490  
BMI (kg/m2) Before 27.71±4.60 -0.07 28.79±4.77 0.30 0.396
 After 27.67±4.53  28.92±5.11  
 P-value# 0.813  0.258  
WHR Before 0.96±0.06 0.07 0.99±0.04 -0.30 0.396
 After 0.96±0.05  0.95±0.19  
 P-value 0.619  0.353  
Zinc (µgr/dl) Before 69.91±6.16 8.69 75.42±7.83 -1.49 0.004
 After 75.78±7.24  74.14±8.43  
 P-value# <0.001  0.329
•P-value based on ANCOVA after  adjustment for baseline values, age and sex; #P-value based on Paired Sample T test
Table 4. The relation between zinc and biochemical  param-
eters and blood pressure before intervention
Variables B P-value* 95% confidence interval
   Lower  Upper
Insulin -0.019 0.403 -1.336 3.254
FBS 0.959 0.738 -0.131 3.254
HOMA-IR -2.649 0.312 -7.886 2.588
HbA1c 1.739 0.364 -2.091 5.569
SBP -0.179 0.202 -0.457 0.100
DBP 0.261 0.184 -0.130 0.653
*Reported based on linear regression 
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hypertension augments  progression of diabetic retinop-
athy (OR: 2.16; 95%CI: 1.03-4.52) (23). Also such as-
sociation was reported by porta et al (OR: 1.50; 95%CI: 
1.03-2.20) (21). As diabetes progresses zinc levels in 
serum tends to decrease. Many studies have shown the 
association of zinc with high blood pressure (5). Chip-
lonkar et al. revealed that serum levels of zinc in subjects 
with hypertension was significantly lower than normo-
tensive ones (24). Jayawardena et al. in a meta-analysis 
assessed the effects of zinc supplementation on diabetic 
indices and concluded that supplementation with zinc 
reduce SBP not DBP (25). Renin-angiotensin system 
activity regulation could be one of the reasons of inverse 
association between zinc and blood pressure. One of the 
main causes of hypertension is activation of renin-angi-
otensin system (17, 26). Tubek et al. in a cross sectional 
study revealed a negative correlation between zinc con-
tent of blood leukocyte and the activity of renin-angi-
otensin system (27). Renin cleaves a peptide, called an-
giotensinogen, into angiotensin I by angiotensin-con-
verting enzyme. Angiotensin I converts to angiotensin 
II and the latter binds to receptors on specific cells that 
surround blood vessels and stimulates their contraction 
to increase blood pressure (28, 29). Zinc also plays a role 
in maintaining the structure and function of more than 
300 types of proteins. Angiotensin-converting enzyme 
is one of the proteins that zinc control its function using 
negative feedback (18, 30). 
Conclusion 
Zinc supplementation in this study significantly 
improved insulin resistance and blood pressure in dia-
betic patients with non-proliferative retinopathy. Ac-
cording to the results, supplementation with zinc is 
effective to control the progression of diabetic retin-
opathy.
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